Compare FGI & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FGI | PCSA |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | 420 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.2M |
| IPO Year | N/A | 2012 |
| Metric | FGI | PCSA |
|---|---|---|
| Price | $8.49 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 303.0K | 64.8K |
| Earning Date | 04-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,000.00 |
| Revenue This Year | $6.38 | N/A |
| Revenue Next Year | $6.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.11 |
| 52 Week High | $12.62 | $8.88 |
| Indicator | FGI | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.14 | 43.93 |
| Support Level | $4.36 | $1.96 |
| Resistance Level | $11.84 | $3.26 |
| Average True Range (ATR) | 2.21 | 0.30 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 55.27 | 8.42 |
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.